Podcast appearances and mentions of David Johnson

In this edition of the Red and Blue Crew podcast, Brad Logan and David Johnson discuss the top coaches in college football, including sixth-year Ole Miss head coach Lane Kiffin, and take a look at the SEC for the 2025-26 season.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Podcast which discusses the main points of The Path to Nibbana   www.dhammasukha.org

Ole Miss in less than 24 hours lost a pair of off-field recruiting staffers, Kelvin Bolden and Alex Brown, to rival LSU and the NFL's Atlanta Falcons, respectively.Brad Logan welcomes in David Johnson to discuss the moves and what comes next.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Ole Miss Spirit contributor Brad Logan is joined by David Johnson of Inside the Rebels to talk Rebel softball's run of transfer commitments, football matters and David's health in an all-new edition of the Red and Blue Crew, powered by Velvet Ditch.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

David Johnson talks softball commits, football and gives a health update

Sheppard Mullin's Restructure THIS! podcast explores the latest trends and controversies in Chapter 11 bankruptcy, commercial insolvency and distressed investing. In this week's episode, David Johnson and Molly Froschauer of Resolution Financial Advisors join host Justin Bernbrock to discuss Assignments for the Benefit of Creditors (ABCs), including advantages and disadvantages compared to traditional bankruptcy options, the various ways an ABC can be leveraged and the acquisition opportunities they offer potential buyers.   What We Discussed in this Episode What is an Assignment for the Benefit of Creditors? What are the advantages and disadvantages of an ABC compared to traditional bankruptcy proceedings? What cost and jurisdictional factors should a distressed company or its board of directors consider when evaluating the various options? How can an ABC be leveraged as an operating company, a going-concern sale or even a prepackaged ABC? How can potential buyers learn about acquisition opportunities involving ABCs? Are there specific companies and industries that aren't well-suited for an ABC?   About the Guests and Host About David M. Johnson, CFA David M. Johnson, CFA, is an accomplished executive with more than 25 years of experience in financial advisory and business restructuring roles. He has honed his skills advising startups, venture-backed companies and established businesses through complex crises, guiding over 400 companies toward recovery and resilience.  Before co-founding Resolution, David served as Senior Managing Director at a middle-market advisory firm, guiding distressed companies for 17 years. He also spent four years with Alvarez & Marsal, Inc., a global turnaround management firm, providing interim management and forensic accounting services for clients that included a national healthcare organization. His expertise spans corporate turnarounds, insolvency management, sales and acquisitions, financial modeling, and valuations.    About Molly Froschauer Molly Froschauer is an experienced insolvency professional who has been advising on bankruptcy and distressed corporate situations for over a decade. Before joining Resolution, she spent seven years with middle-market professional services firms, specializing in corporate distress. Molly's career also includes practicing as a bankruptcy attorney and serving as a general manager for an out-of-court insolvency service provider and liquidation agent. Her work has spanned managing creditor meetings, advocating for business debt solutions and educating trade creditors on navigating debt resolution. As an editor for the National Association for Credit Management's Manual of Credit and Commercial Laws, Molly oversaw more than 50 Assignments for the Benefit of Creditors, out-of-court workouts and engagements through the bankruptcy courts.   About Justin Bernbrock Justin Bernbrock is a partner in the Finance and Bankruptcy Practice Group in Sheppard Mullin's Chicago office, where he focuses on all aspects of corporate restructuring, bankruptcy and financial distress. He represents clients across a wide range of matters, including debtor and creditor representations. He has substantial experience in out-of-court and in-court restructurings, primarily in the Southern District of New York, Eastern District of Virginia, District of Delaware and Southern District of Texas.   Contact Information David M. Johnson, CFA Molly Froschauer Justin Bernbrock   Thank you for listening! Don't forget to SUBSCRIBE to the show to receive every new episode delivered straight to your podcast player every week. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show in Apple Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.

Ole Miss Spirit contributor Brad Logan is joined by David Johnson of Inside the Rebels to preview the 2025 Ole Miss football offense and pending recruiting commitment in this edition of the Red and Blue Crew Podcast, powered by Velvet Ditch.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

06-23-2025 David Johnson Learn more about the interview and get additional links here: https://usabusinessradio.com/why-pr-is-essential-for-businesses/ Subscribe to the best of our content here: https://priceofbusiness.substack.com/ Subscribe to our YouTube channel here: https://www.youtube.com/channel/UCywgbHv7dpiBG2Qswr_ceEQ

Join us from Royal Ascot on day 3 as Nick is joined by Charlotte Greenway on course, this time from the pre parade ring. They begin by reflecting the action from day 2 and Ombudsman's performance in the Prince of Wales's Stakes and David Johnson of Timeform discusses what sort of figure he might earn. Adam Mills of Total Performance Data also looks at whether the two Ballydoyle horses went too quick on the front end, ruining there chances after the first couple of furlongs. Eve Johnson Haughton very kindly joins us via FaceTime after yesterday's emotional success in the Windsor Castle Stakes and thinks she has a Group 3 filly running in a handicap tomorrow. Then Nick and Charlotte move onto today's racing and look at the Gold Cup and whether Trawlerman can capitalise on the absence of Kyprios whilst we also hear from Orlando at Fitzdares on the betting for day 3's feature. Of course, Lisa Tan has the latest fashion tips and Grainne Hurst, CEO of the betting and gaming council on the charity ascent if the Britannia Stakes, run this afternoon.

Join hosts Brad Logan and David Johnson as the crew discusses the wild world of NIL in the college space. Presented by: The Landshark, The Velvet Ditch and the Hearn Law FirmAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Live from Royal Ascot on day 2 and Nick is alongside ITV's Matt Chapman who has a spring in his step and they begin by reflecting on yesterday's racing including Field of Gold's fabulous performance in the St Jame's Palace Stakes. Time form's David Johnson looks at what sort of rating that performance might earn him before Adam Mills of Total Performance data looks at the ride Mark Zahra gave Docklands to win the opening contest and why he made the difference. Lisa Tan has plenty of fashion updates for us from the course yesterday before Aidan Butler and Nick Smith discuss the relatively new incentive for American 2yr olds coming to Royal Ascot and why it's so attractive and finally Fitzdares provide and update on the market for today's feature the Prince of Wales's, in which Matt Chapman believes he's found the bet of the year.

Join us from Royal Ascot on day 3 as Nick is joined by Charlotte Greenway on course, this time from the pre parade ring. They begin by reflecting the action from day 2 and Ombudsman's performance in the Prince of Wales's Stakes and David Johnson of Timeform discusses what sort of figure he might earn. Adam Mills of Total Performance Data also looks at whether the two Ballydoyle horses went too quick on the front end, ruining there chances after the first couple of furlongs. Eve Johnson Haughton very kindly joins us via FaceTime after yesterday's emotional success in the Windsor Castle Stakes and thinks she has a Group 3 filly running in a handicap tomorrow. Then Nick and Charlotte move onto today's racing and look at the Gold Cup and whether Trawlerman can capitalise on the absence of Kyprios whilst we also hear from Orlando at Fitzdares on the betting for day 3's feature. Of course, Lisa Tan has the latest fashion tips and Grainne Hurst, CEO of the betting and gaming council on the charity ascent if the Britannia Stakes, run this afternoon.

Join hosts Brad Logan and David Johnson as the crew discusses the wild world of NIL in college athletics. -Presented by: The Velvet Ditch, The Landshark and the Hearn Law Firm

Live from Royal Ascot on day 2 and Nick is alongside ITV's Matt Chapman who has a spring in his step and they begin by reflecting on yesterday's racing including Field of Gold's fabulous performance in the St Jame's Palace Stakes. Time form's David Johnson looks at what sort of rating that performance might earn him before Adam Mills of Total Performance data looks at the ride Mark Zahra gave Docklands to win the opening contest and why he made the difference. Lisa Tan has plenty of fashion updates for us from the course yesterday before Aidan Butler and Nick Smith discuss the relatively new incentive for American 2yr olds coming to Royal Ascot and why it's so attractive and finally Fitzdares provide and update on the market for today's feature the Prince of Wales's, in which Matt Chapman believes he's found the bet of the year.

Ole Miss Spirit contributor Brad Logan and David Johnson recap a big official visit weekend for Rebel football, as well as break down the recruiting efforts of Jamie Trachsel and Rebel softball. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Join hosts David Johnson and Brad Logan as they recap the big football official visit weekend on campus and also touch on softball recruiting.

David Johnson and Brad Logan discuss the success of Ole Miss Athletics, plus a check-in on David's recent cancer diagnosis, in the latest edition of the Red & Blue Crew Podcast presented by The Velvet Ditch.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Red and Blue Crew Podcast co-host David Johnson provides a health update.

Senator Ron Johnson, Strategic Vision's David Johnson, American Principles Project's Anthony La Bruna, The Federalist's John Daniel Davidson, McIver Institute's Bill Osmulski Replaying Senator Ron Johnson

In this edition of the Red & Blue Crew Podcast, presented by The Velvet Ditch Seafood Restaurant and Bar, Brad Logan and David Johnson discuss Sunday's Southern Elite MegaCamp, with a focus on Ole Miss targets. Plus, some final baseball and softball thoughts.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Nick and Lydia give you the ultimate pre-Derby special, featuring the first major broadcast interview with new Jockey Club CEO Jim Mullen plus Derby Chance or No Chance, and much more on the great race and Festival. Plus, Tote CEO Alex Frost on Worldpool, Henry Beeby on the London Sale, and Timeform's David Johnson on why Ruling Court might be up against it in the Derby.

Join Brad Logan and David Johnson as they recap both the Ole Miss baseball and softball postseason runs.

Join Brad Logan and David Johnson as they discuss the Ole Miss Softball team breaking records and heading to the WCWS

Send us a textFlashing back to episode #72 of Fabulous Film & Friends way back in 2023, we covered Mission: Impossible – Dead Reckoning Part 1 and so we here on FFF felt duty bound to our fans to give our take on its follow up and what could very possibly be the final sequel to the entire M:I franchise, 2025's Mission: Impossible – The Final Reckoning directed by Christopher McQuarrie and starring Tom Cruise, Hayley Atwell, Simon Pegg, Ving Rhames, Pom Klementieff, Esai Morales, Shea Whigham, Greg Tarzan Davis, Henry Czerny and Angela Bassett. Keeping continuity, my guests this week are returnees from the 2023 podcast, my blockbuster crew David Johnson, DMD and Burton Brown. Does anyone remember what happened in Mission Impossible Dead Reckoning Part 1? Here's a callback to my synopsis from that podcast:Ethan Hunt and his team of Mission Impossiblers have to go rogue yet again to stop the world from  yada yada yada. Same old crap megalomaniac with a weapon this time it's AI. Or something.  Esai Morales is involved. I fell asleep twice so I didn't quite catch the relationship between the AI and Morales' Gabriel character.This movie seemed like more of the same old same old. But as a Tom Cruise running movie, it's a masterpiece, reaching an operatic Death in Venice level of running sophistication. So how does 2025's big follow up differ?This time Ethan Hunt and his rag tag team of crack superspies have to stop the AI Entity from blowing up the world as well as Gabriel from trying to harness its unbelievable power. Yet, instead of  running extravaganza, we are treated to the biggest boldest, hands down, accept no substitutes granddaddy of all info dump and flashback movies. Is it the best, the worst or somewhere in the middle of the series?Find out! Watch the video podcast on Youtube:https://youtu.be/dZfi-Cr8v20                                                                                                                                                       

State Assembly Rep Lindee Brill, Author Dr. Gilda Carle, JunkScience.com's Steve Milloy, Strategic Vision's David Johnson, Moms for Liberty Scarlett Johnson, Wisconsin Institute for Law and Liberty's Dan Lennington

This week's interview is with a new friend of the show, David Johnson, aka Doktor High! Doktor High is a cannabis content creator and lifestyle coach who has been involved in the cannabis industry for decades, working across many areas of the scene. His latest venture explores the cutting edge of technology, using AI to create music and cannabis-related content. In this episode, we dive into the rise of AI, how tools like ChatGPT are helping creators, and we also talk about a powerful music-generation tool called Suno. This was a fun and insightful conversation, where we learned a lot about how AI can be used to produce original content, whether you're into cannabis, music, or anything else creative. So give it a listen, and maybe even get inspired to try making something with the help of your own AI assistant. The future is here! If you have any suggestions for guest to be on our cannabis podcast then please feel free to contact us on our website, Discord server, or any of your favourite social networks. Visit our website for links.  Website: https://highonhomegrown.com Discord: https://discord.gg/sqYGkF4xyQ Youtube: https://www.youtube.com/highonhomegrown Thank you for downloading and listening to our cannabis podcast! 

Subscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsWhen your child is sick, do you know what's really in the medicine you're giving them? In this powerful episode, Dr. Taz sits down with David Johnson, co-founder and CEO of Genexa, the first clean medicine company in the U.S. Born into a naturopathic family and driven by fatherhood, David shares the emotional and entrepreneurial journey that led him to question what's hiding in over-the-counter medications and how 90–95% of most medicines are made up of inactive ingredients, many of which are banned in other countries.Together, they dive into:Why common ingredients like red dye, titanium dioxide, and artificial sweeteners may be harming our children.The difference between "natural," "organic," and truly "clean" medicine.How Genexa is disrupting Big Pharma from the inside out and the personal cost of that battle.The heartbreaking moment that changed everything for David and shaped his mission.What YOU need to know to protect your family and advocate for better health policies.Whether you're a parent, practitioner, or wellness advocate, this episode will leave you questioning the status quo and inspired to demand better.Thank you to our sponsor: OneSkinGet 15% off your first order with the code DRTAZ at oneskin.co/drtazConnect further to Hol+ at https://holplus.co/- Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+.About David JohnsonDavid Johnson is the Co-Founder and CEO of Genexa®, the first clean medicine company. Born and raised in a family of naturopathic practitioners, David has been connected to natural health and wellness his entire life. After becoming a father in 2010, he was surprised to discover the artificial dyes, flavors, preservatives, and common allergens found in most children's over-the-counter medicines. Seeing a need for clean options, David co-founded Genexa in 2014 to create medicine made with the same effective active ingredients as the leading brands, but without unnecessary artificial additives. Genexa believes in putting People Over Everything® and is on a mission to revolutionize the medicine aisle by offering clean choices for families everywhere.Stay ConnectedSubscribe to the audio podcast: https://holplus.transistor.fm/subscribeSubscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsFollow Dr. Taz on Instagram: https://www.instagram.com/drtazmd/https://www.instagram.com/liveholplus/Join the conversation on X: https://x.com/@drtazmdTikTok: https://www.tiktok.com/@drtazmdFacebook: https://www.facebook.com/drtazmd/Learn more about Genexahttps://www.genexa.com/Host & Production TeamHost: Dr. Taz; Produced by Rainbow Creative (Executive Producer: Matthew Jones; Lead Producer: Lauren Feighan; Editors: Jeremiah Schultz and Patrick Edwards)Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+0:00 What's really in your child's medicine?2:32 Meet David Johnson, co-founder of Genexa5:17 Why David started the clean medicine revolution8:32 Hidden allergens & toxic load from OTC drugs11:47 The challenge of disrupting Big Pharma15:03 What clean medicine actually means18:13 Ingredients banned in Europe, but legal in the U.S.22:17 Why parents & doctors are waking up now29:17 Building a business with passion and purpose37:17 How stress impacts your health (David's gut issues)45:17 What's next for Genexa – and a powerful final message

Join hosts David Johnson and Brad Logan as they talk about the latest Ole Miss news.

In this webinar recording, WrenchWay and ASE introduce the School Assist All-Star Awards—a new program recognizing schools and shops making a real impact in promoting automotive and diesel careers. David Johnson, President & CEO of ASE, joins WrenchWay Co-Founders Jay Goninen and Mark Wilson to talk about the award criteria, the importance of strong school-shop partnerships, and how these relationships support shop retention and recruitment.View the Webinar Video Learn More About School AssistAbout Our Guests:David JohnsonPresident & CEO, ASEMark WilsonPresident & CEO, WrenchWaySponsor:National Institute for Automotive Service Excellence (ASE)About Our Host:Jay GoninenCo-Founder & President, WrenchWayjayg@wrenchway.com | 608.716.2122WrenchWay Resources:For Technicians & StudentsCompare & Explore Technician Pay: View salary information for automotive, diesel, and collision technicians near you at wrenchway.com/pay.Find Your Ideal Shop or Dealership: Looking for the best places to work? Discover and research the best shop or dealership for you at wrenchway.com/shops.For Shops & DealershipsHire Top Talent & Assist Schools: Connect with skilled technicians, engage with schools, and help elevate the auto and diesel industry with WrenchWay Top Shop Memberships. For Auto, Diesel, & CTE Instructors:Support Your Program & Connect with Industry: Get resources and equipment for your program and grow your industry partnerships with WrenchWay's free solutions for schools.Connect with us on social: Facebook Instagram Twitter LinkedIn YouTube TikTok

Fresh from covering the 17th National Congress on School Transportation, Taylor joins Ryan and Tony to discuss conversations and takeaways on the school bus safety recommendations that will make it into the National School Transportation Specifications and Procedures Manual. Upcoming STN EXPO West and TSD Conference sessions will discuss tariffs and manufacturing developments, safety in and around the bus, and pertinent updates for transporters of students with disabilities. David Johnson, executive director for the Iowa Pupil Transportation Association, joins us to share his perspectives and some local flavor as well. Read more about NCST. Episode sponsor: Transfinder.

Listen to ASCO's JCO Oncology Practice, Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last” by Dr. David Johnson, who is a clinical oncologist at University of Texas Southwestern Medical School. The article is followed by an interview with Johnson and host Dr. Mikkael Sekeres. Through humor and irony, Johnson critiques how overspecialization and poor presentation practices have eroded what was once internal medicine's premier educational forum. Transcript Narrator: An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last, by David H. Johnson, MD, MACP, FASCO   Over the past five decades, I have attended hundreds of medical conferences—some insightful and illuminating, others tedious and forgettable. Among these countless gatherings, Medical Grand Rounds (MGRs) has always held a special place. Originally conceived as a forum for discussing complex clinical cases, emerging research, and best practices in patient care, MGRs served as a unifying platform for clinicians across all specialties, along with medical students, residents, and other health care professionals. Expert speakers—whether esteemed faculty or distinguished guests—would discuss challenging cases, using them as a springboard to explore the latest advances in diagnosis and treatment. During my early years as a medical student, resident, and junior faculty member, Grand Rounds consistently attracted large, engaged audiences. However, as medicine became increasingly subspecialized, attendance began to wane. Lectures grew more technically intricate, often straying from broad clinical relevance. The patient-centered discussions that once brought together diverse medical professionals gradually gave way to hyperspecialized presentations. Subspecialists, once eager to share their insights with the wider medical community, increasingly withdrew to their own specialty-specific conferences, further fragmenting the exchange of knowledge across disciplines. As a former Chair of Internal Medicine and a veteran of numerous MGRs, I observed firsthand how these sessions shifted from dynamic educational exchanges to highly specialized, often impenetrable discussions. One of the most striking trends in recent years has been the decline in presentation quality at MGR—even among local and visiting world-renowned experts. While these speakers are often brilliant clinicians and investigators, they can also be remarkably poor lecturers, delivering some of the most uninspiring talks I have encountered. Their presentations are so consistently lackluster that one might suspect an underlying strategy at play—an unspoken method to ensure that they are never invited back. Having observed this pattern repeatedly, I am convinced that these speakers must be adhering to a set of unwritten rules to avoid future MGR presentations. To assist those unfamiliar with this apparent strategy, I have distilled the key principles that, when followed correctly, all but guarantee that a presenter will not be asked to give another MGR lecture—thus sparing them the burden of preparing one in the future. Drawing on my experience as an oncologist, I illustrate these principles using an oncology-based example although I suspect similar rules apply across other subspecialties. It will be up to my colleagues in cardiology, endocrinology, rheumatology, and beyond to identify and document their own versions—tasks for which I claim no expertise. What follows are the seven “Rules for Presenting a Bad Medical Oncology Medical Grand Rounds.” 1.  Microscopic Mayhem: Always begin with an excruciatingly detailed breakdown of the tumor's histology and molecular markers, emphasizing how these have evolved over the years (eg, PAP v prostate-specific antigen)—except, of course, when they have not (eg, estrogen receptor, progesterone receptor, etc). These nuances, while of limited relevance to general internists or most subspecialists (aside from oncologists), are guaranteed to induce eye-glazing boredom and quiet despair among your audience. 2. TNM Torture: Next, cover every nuance of the newest staging system … this is always a real crowd pleaser. For illustrative purposes, show a TNM chart in the smallest possible font. It is particularly helpful if you provide a lengthy review of previous versions of the staging system and painstakingly cover each and every change in the system. Importantly, this activity will allow you to disavow the relevance of all previous literature studies to which you will subsequently refer during the course of your presentation … to wit—“these data are based on the OLD staging system and therefore may not pertain …” This phrase is pure gold—use it often if you can. NB: You will know you have “captured” your audience if you observe audience members “shifting in their seats” … it occurs almost every time … but if you have failed to “move” the audience … by all means, continue reading … there is more! 3. Mechanism of Action Meltdown: Discuss in detail every drug ever used to treat the cancer under discussion; this works best if you also give a detailed description of each drug's mechanism of action (MOA). General internists and subspecialists just LOVE hearing a detailed discussion of the drug's MOA … especially if it is not at all relevant to the objectives of your talk. At this point, if you observe a wave of slack-jawed faces slowly slumping toward their desktops, you will know you are on your way to successfully crushing your audience's collective spirit. Keep going—you are almost there. 4. Dosage Deadlock: One must discuss “dose response” … there is absolutely nothing like a dose response presentation to a group of internists to induce cries of anguish. A wonderful example of how one might weave this into a lecture to generalists or a mixed audience of subspecialists is to discuss details that ONLY an oncologist would care about—such as the need to dose escalate imatinib in GIST patients with exon 9 mutations as compared with those with exon 11 mutations. This is a definite winner! 5. Criteria Catatonia: Do not forget to discuss the newest computed tomography or positron emission tomography criteria for determining response … especially if you plan to discuss an obscure malignancy that even oncologists rarely encounter (eg, esthesioneuroblastoma). Should you plan to discuss a common disease you can ensure ennui only if you will spend extra time discussing RECIST criteria. Now if you do this well, some audience members may begin fashioning their breakfast burritos into projectiles—each one aimed squarely at YOU. Be brave … soldier on! 6. Kaplan-Meier Killer: Make sure to discuss the arcane details of multiple negative phase II and III trials pertaining to the cancer under discussion. It is best to show several inconsequential and hard-to-read Kaplan-Meier plots. To make sure that you do a bad job, divide this portion of your presentation into two sections … one focused on adjuvant treatment; the second part should consist of a long boring soliloquy on the management of metastatic disease. Provide detailed information of little interest even to the most ardent fan of the disease you are discussing. This alone will almost certainly ensure that you will never, ever be asked to give Medicine Grand Rounds again. 7. Lymph Node Lobotomy: For the coup de grâce, be sure to include an exhaustive discussion of the latest surgical techniques, down to the precise number of lymph nodes required for an “adequate dissection.” To be fair, such details can be invaluable in specialized settings like a tumor board, where they send subspecialists into rapturous delight. But in the context of MGR—where the audience spans multiple disciplines—it will almost certainly induce a stultifying torpor. If dullness were an art, this would be its masterpiece—capable of lulling even the most caffeinated minds into a stupor. If you have carefully followed the above set of rules, at this point, some members of the audience should be banging their heads against the nearest hard surface. If you then hear a loud THUD … and you're still standing … you will know you have succeeded in giving the world's worst Medical Grand Rounds!   Final Thoughts I hope that these rules shed light on what makes for a truly dreadful oncology MGR presentation—which, by inverse reasoning, might just serve as a blueprint for an excellent one. At its best, an outstanding lecture defies expectations. One of the most memorable MGRs I have attended, for instance, was on prostaglandin function—not a subject typically associated with edge-of-your-seat suspense. Given by a biochemist and physician from another subspecialty, it could have easily devolved into a labyrinth of enzymatic pathways and chemical structures. Instead, the speaker took a different approach: rather than focusing on biochemical minutiae, he illustrated how prostaglandins influence nearly every major physiologic system—modulating inflammation, regulating cardiovascular function, protecting the gut, aiding reproduction, supporting renal function, and even influencing the nervous system—without a single slide depicting the prostaglandin structure. The result? A room full of clinicians—not biochemists—walked away with a far richer understanding of how prostaglandins affect their daily practice. What is even more remarkable is that the talk's clarity did not just inform—it sparked new collaborations that shaped years of NIH-funded research. Now that was an MGR masterpiece. At its core, effective scientific communication boils down to three deceptively simple principles: understanding your audience, focusing on relevance, and making complex information accessible.2 The best MGRs do not drown the audience in details, but rather illuminate why those details matter. A great lecture is not about showing how much you know, but about ensuring your audience leaves knowing something they didn't before. For those who prefer the structured wisdom of a written guide over the ramblings of a curmudgeon, an excellent review of these principles—complete with a handy checklist—is available.2 But fair warning: if you follow these principles, you may find yourself invited back to present another stellar MGRs. Perish the thought! Dr. Mikkael SekeresHello and welcome to JCO's Cancer Stories: The Art of Oncology, which features essays and personal reflections from authors exploring their experience in the oncology field. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami.  What a pleasure it is today to be joined by Dr. David Johnson, clinical oncologist at the University of Texas Southwestern Medical School. In this episode, we will be discussing his Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last."  Our guest's disclosures will be linked in the transcript.  David, welcome to our podcast and thanks so much for joining us. Dr. David JohnsonGreat to be here, Mikkael. Thanks for inviting me. Dr. Mikkael SekeresI was wondering if we could start with just- give us a sense about you. Can you tell us about yourself? Where are you from? And walk us through your career. Dr. David JohnsonSure. I grew up in a small rural community in Northwest Georgia about 30 miles south of Chattanooga, Tennessee, in the Appalachian Mountains. I met my wife in kindergarten. Dr. Mikkael SekeresOh my. Dr. David JohnsonThere are laws in Georgia. We didn't get married till the third grade. But we dated in high school and got married after college. And so we've literally been with one another my entire life, our entire lives. Dr. Mikkael SekeresMy word. Dr. David JohnsonI went to medical school in Georgia. I did my training in multiple sites, including my oncology training at Vanderbilt, where I completed my training. I spent the next 30 years there, where I had a wonderful career. Got an opportunity to be a Division Chief and a Deputy Director of, and the founder of, a cancer center there. And in 2010, I was recruited to UT Southwestern as the Chairman of Medicine. Not a position I had particularly aspired to, but I was interested in taking on that challenge, and it proved to be quite a challenge for me. I had to relearn internal medicine, and really all the subspecialties of medicine really became quite challenging to me. So my career has spanned sort of the entire spectrum, I suppose, as a clinical investigator, as an administrator, and now as a near end-of-my-career guy who writes ridiculous articles about grand rounds. Dr. Mikkael SekeresNot ridiculous at all. It was terrific. What was that like, having to retool? And this is a theme you cover a little bit in your essay, also, from something that's super specialized. I mean, you have had this storied career with the focus on lung cancer, and then having to expand not only to all of hematology oncology, but all of medicine. Dr. David JohnsonIt was a challenge, but it was also incredibly fun. My first few days in the chair's office, I met with a number of individuals, but perhaps the most important individuals I met with were the incoming chief residents who were, and are, brilliant men and women. And we made a pact. I promised to teach them as much as I could about oncology if they would teach me as much as they could about internal medicine. And so I spent that first year literally trying to relearn medicine. And I had great teachers. Several of those chiefs are now on the faculty here or elsewhere. And that continued on for the next several years. Every group of chief residents imparted their wisdom to me, and I gave them what little bit I could provide back to them in the oncology world. It was a lot of fun. And I have to say, I don't necessarily recommend everybody go into administration. It's not necessarily the most fun thing in the world to do. But the opportunity to deal one-on-one closely with really brilliant men and women like the chief residents was probably the highlight of my time as Chair of Medicine. Dr. Mikkael SekeresThat sounds incredible. I can imagine, just reflecting over the two decades that I've been in hematology oncology and thinking about the changes in how we diagnose and care for people over that time period, I can only imagine what the changes had been in internal medicine since I was last immersed in that, which would be my residency. Dr. David JohnsonWell, I trained in the 70s in internal medicine, and what transpired in the 70s was kind of ‘monkey see, monkey do'. We didn't really have a lot of understanding of pathophysiology except at the most basic level. Things have changed enormously, as you well know, certainly in the field of oncology and hematology, but in all the other fields as well. And so I came in with what I thought was a pretty good foundation of knowledge, and I realized it was completely worthless, what I had learned as an intern and resident. And when I say I had to relearn medicine, I mean, I had to relearn medicine. It was like being an intern. Actually, it was like being a medical student all over again. Dr. Mikkael SekeresOh, wow. Dr. David JohnsonSo it's quite challenging.  Dr. Mikkael SekeresWell, and it's just so interesting. You're so deliberate in your writing and thinking through something like grand rounds. It's not a surprise, David, that you were also deliberate in how you were going to approach relearning medicine. So I wonder if we could pivot to talking about grand rounds, because part of being a Chair of Medicine, of course, is having Department of Medicine grand rounds. And whether those are in a cancer center or a department of medicine, it's an honor to be invited to give a grand rounds talk. How do you think grand rounds have changed over the past few decades? Can you give an example of what grand rounds looked like in the 1990s compared to what they look like now? Dr. David JohnsonWell, I should all go back to the 70s and and talk about grand rounds in the 70s. And I referenced an article in my essay written by Dr. Ingelfinger, who many people remember Dr. Ingelfinger as the Ingelfinger Rule, which the New England Journal used to apply. You couldn't publish in the New England Journal if you had published or publicly presented your data prior to its presentation in the New England Journal. Anyway, Dr. Ingelfinger wrote an article which, as I say, I referenced in my essay, about the graying of grand rounds, when he talked about what grand rounds used to be like. It was a very almost sacred event where patients were presented, and then experts in the field would discuss the case and impart to the audience their wisdom and knowledge garnered over years of caring for patients with that particular problem, might- a disease like AML, or lung cancer, or adrenal insufficiency, and talk about it not just from a pathophysiologic standpoint, but from a clinician standpoint. How do these patients present? What do you do? How do you go about diagnosing and what can you do to take care of those kinds of patients? It was very patient-centric. And often times the patient, him or herself, was presented at the grand rounds. And then experts sitting in the front row would often query the speaker and put him or her under a lot of stress to answer very specific questions about the case or about the disease itself.  Over time, that evolved, and some would say devolved, but evolved into more specialized and nuanced presentations, generally without a patient present, or maybe even not even referred to, but very specifically about the molecular biology of disease, which is marvelous and wonderful to talk about, but not necessarily in a grand round setting where you've got cardiologists sitting next to endocrinologists, seated next to nephrologists, seated next to primary care physicians and, you know, an MS1 and an MS2 and et cetera. So it was very evident to me that what I had witnessed in my early years in medicine had really become more and more subspecialized. As a result, grand rounds, which used to be packed and standing room only, became echo chambers. It was like a C-SPAN presentation, you know, where local representative got up and gave a talk and the chambers were completely empty. And so we had to go to do things like force people to attend grand rounds like a Soviet Union-style rally or something, you know. You have to pay them to go. But it was really that observation that got me to thinking about it.  And by the way, I love oncology and I'm, I think there's so much exciting progress that's being made that I want the presentations to be exciting to everybody, not just to the oncologist or the hematologist, for example. And what I was witnessing was kind of a formula that, almost like a pancake formula, that everybody followed the same rules. You know, “This disease is the third most common cancer and it presents in this way and that way.” And it was very, very formulaic. It wasn't energizing and exciting as it had been when we were discussing individual patients. So, you know, it just is what it is. I mean, progress is progress and you can't stop it. And I'm not trying to make America great again, you know, by going back to the 70s, but I do think sometimes we overthink what medical grand rounds ought to be as compared to a presentation at ASH or ASCO where you're talking to subspecialists who understand the nuances and you don't have to explain the abbreviations, you know, that type of thing. Dr. Mikkael SekeresSo I wonder, you talk about the echo chamber of the grand rounds nowadays, right? It's not as well attended. It used to be a packed event, and it used to be almost a who's who of, of who's in the department. You'd see some very famous people who would attend every grand rounds and some up-and-comers, and it was a chance for the chief residents to shine as well. How do you think COVID and the use of Zoom has changed the personality and energy of grand rounds? Is it better because, frankly, more people attend—they just attend virtually. Last time I attended, I mean, I attend our Department of Medicine grand rounds weekly, and I'll often see 150, 200 people on the Zoom. Or is it worse because the interaction's limited? Dr. David JohnsonYeah, I don't want to be one of those old curmudgeons that says, you know, the way it used to be is always better. But there's no question that the convenience of Zoom or similar media, virtual events, is remarkable. I do like being able to sit in my office where I am right now and watch a conference across campus that I don't have to walk 30 minutes to get to. I like that, although I need the exercise. But at the same time, I think one of the most important aspects of coming together is lost with virtual meetings, and that's the casual conversation that takes place. I mentioned in my essay an example of the grand rounds that I attended given by someone in a different specialty who was both a physician and a PhD in biochemistry, and he was talking about prostaglandin metabolism. And talk about a yawner of a title; you almost have to prop your eyelids open with toothpicks. But it turned out to be one of the most fascinating, engaging conversations I've ever encountered. And moreover, it completely opened my eyes to an area of research that I had not been exposed to at all. And it became immediately obvious to me that it was relevant to the area of my interest, which was lung cancer. This individual happened to be just studying colon cancer. He's not an oncologist, but he was studying colon cancer. But it was really interesting what he was talking about. And he made it very relevant to every subspecialist and generalist in the audience because he talked about how prostaglandin has made a difference in various aspects of human physiology.  The other grand rounds which always sticks in my mind was presented by a long standing program director at my former institution of Vanderbilt. He's passed away many years ago, but he gave a fascinating grand rounds where he presented the case of a homeless person. I can't remember the title of his grand rounds exactly, but I think it was “Care of the Homeless” or something like that. So again, not something that necessarily had people rushing to the audience. What he did is he presented this case as a mysterious case, you know, “what is it?” And he slowly built up the presentation of this individual who repeatedly came to the emergency department for various and sundry complaints. And to make a long story short, he presented a case that turned out to be lead poisoning. Everybody was on the edge of their seat trying to figure out what it was. And he was challenging members of the audience and senior members of the audience, including the Cair, and saying, “What do you think?” And it turned out that the patient became intoxicated not by eating paint chips or drinking lead infused liquids. He was burning car batteries to stay alive and inhaling lead fumes, which itself was fascinating, you know, so it was a fabulous grand rounds. And I mean, everybody learned something about the disease that they might otherwise have ignored, you know, if it'd been a title “Lead Poisoning”, I'm not sure a lot of people would have shown up. Dr. Mikkael Sekeres That story, David, reminds me of Tracy Kidder, who's a master of the nonfiction narrative, will choose a subject and kind of just go into great depth about it, and that subject could be a person. And he wrote a book called Rough Sleepers about Jim O'Connell - and Jim O'Connell was one of my attendings when I did my residency at Mass General - and about his life and what he learned about the homeless. And it's this same kind of engaging, “Wow, I never thought about that.” And it takes you in a different direction.  And you know, in your essay, you make a really interesting comment. You reflect that subspecialists, once eager to share their insight with the wider medical community, increasingly withdraw to their own specialty specific conferences, further fragmenting the exchange of knowledge across disciplines. How do you think this affects their ability to gain new insights into their research when they hear from a broader audience and get questions that they usually don't face, as opposed to being sucked into the groupthink of other subspecialists who are similarly isolated? Dr. David Johnson That's one of the reasons I chose to illustrate that prostaglandin presentation, because again, that was not something that I specifically knew much about. And as I said, I went to the grand rounds more out of a sense of obligation than a sense of engagement. Moreover, our Chair at that institution forced us to go, so I was there, not by choice, but I'm so glad I was, because like you say, I got insight into an area that I had not really thought about and that cross pollination and fertilization is really a critical aspect. I think that you can gain at a broad conference like Medical Grand Rounds as opposed to a niche conference where you're talking about APL. You know, everybody's an APL expert, but they never thought about diabetes and how that might impact on their research. So it's not like there's an ‘aha' moment at every Grand Rounds, but I do think that those kinds of broad based audiences can sometimes bring a different perspective that even the speaker, him or herself had not thought of. Dr. Mikkael SekeresI think that's a great place to end and to thank David Johnson, who's a clinical oncologist at the University of Texas Southwestern Medical School and just penned the essay in JCO Art of Oncology Practice entitled "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last."  Until next time, thank you for listening to JCO's Cancer Stories: The Art of Oncology. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all of ASCO's shows at asco.org/podcasts.  David, once again, I want to thank you for joining me today. Dr. David JohnsonThank you very much for having me. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Show notes: Like, share and subscribe so you never miss an episode and leave a rating or review.  Guest Bio: Dr David Johnson is a clinical oncologist at the University of Texas Southwestern Medical School.

In this episode, microbiologist and co-creator of the Johnson-Su bioreactor, Dr. David Johnson describes the microbiological profile of a struggling plant.   Subscribe for more content on sustainable farming, market farming tips, and business insights!   Get market farming tools, seeds, and supplies at Modern Grower. Follow Modern Grower:  Instagram  Instagram Listen to other podcasts on the Modern Grower Podcast Network:  Carrot Cashflow  Farm Small Farm Smart  Farm Small Farm Smart Daily  The Growing Microgreens Podcast  The Urban Farmer Podcast  The Rookie Farmer Podcast  In Search of Soil Podcast Check out Diego's books:  Sell Everything You Grow on Amazon   Ready Farmer One on Amazon **** Modern Grower and Diego Footer participate in the Amazon Services LLC. Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.

In this weeks episode we are joined by Barbara McClintock!Barbara McClintock is an American illustrator and author of over 40 books for children. Her books have received numerous awards and citations, including five New York Times Best Illustrated Picture Book Awards, four ALA Notable Book Citations, a Boston Globe/Horn Book Honor Award, a China Times Best Illustrated Books Award, and a British Fantasy Award. One of her books is a best-selling title in Japan.Her artwork has been exhibited and is in the collections of libraries, museums and galleries around the world.She has lectured about her work nationally and internationally, and is currently teaching classes on creating children's books at Wesleyan University. She has served on the board of directors of the Eric Carle Museum, and chaired the Original Art Show at the Society of Illustrators.Barbara is self-educated as an illustrator, learning by studying and copying artwork from books checked out of public libraries.Originally from New Jersey and North Dakota, she now resides in northeastern CT with her partner, the illustrator David Johnson, and their three overly-helpful cats.Buy her latest book here: https://bookshop.org/a/19191/9781534418509Follow her here: https://www.instagram.com/barbaramcclintockart/Support the show

David Johnson discusses Romans 1:28—“And even as they did not like to retain God in their knowledge, God gave them over to a debased mind, to do those things which are not fitting.”

Sean Gleason, the CEO of PBR (Professional Bull Riders) talks to KRLD's David Johnson about the big event coming to North Texas.

Brad Logan and David Johnson are joined by Zebra Tent founders Lantz and Jane Foster.

Send us a textWelcome to our 102nd Blockbuster Episode, The BEST of Jared Hess Part 2: Enter Jack Black where we will discuss and dissect the afore-mentioned actor and director pairings starting with 2006's Nacho Libre starring Jack Black, Héctor Jiménez, Ana de la Reguera, Darius Rose and Peter Stormare compared to 2025's megahit blockbuster A Minecraft Movie starring Black again, Jason Momoa, Emma Myers, Sebastian Eugene Hansen, Danielle Brooks Dawn, Jennifer Coolidge and  Jemaine Clement. My solitary guest tonight is the only muchacho bold enough to help me fill our pockets with cinematic diamonds — a man worthy of a hearty Roman forearm handshake. Please welcome fellow former Treasure Valley dweller and ultimate fighting challenge boss, Dr. David Johnson, DMD.Before we enter that rickety old mineshaft, the synopses: In Nacho Libre:Ignacio, A humble Mexican monastery cook  dreams of becoming a word famous luchador to earn respect and help the orphans he cares for. Against all odds — and with plenty of epic fails — he embraces his destiny in the wrestling ring.A Minecraft Movie (2025)Siblings Henry and Natalie, new residents in the town of Chuglass Idaho, along with has been gaming world champ Garrett Garrison and their realtor Dawn, arewhisked  into the blocky Overworld, where they must team up with Steve—a legendary Minecrafter—to survive and find their way home.  How do these two films rank in Jared Hess' filmography?  Find out!   Watch the video on Youtube:https://youtu.be/-gj94ElQobk     

David Johnson discusses Proverbs 29:2—“When the righteous are in authority, the people rejoice; but when a wicked man rules, the people groan.”

Rafael Lizardi, the Chief Financial Officer of Texas Instruments (Nasdaq: TXN), joined KRLD's David Johnson in the CEO Spotlight.

Bob Jordan, president and CEO, Southwest Airlines Co. (NYSE: LUV), joined KRLD's David Johnson in the CEO Spotlight.

Dallas-based Southwest Airlines reported a loss of $149-million in the first quarter which still beat Wall Street expectations. CEO Bob Jordan told KRLD's David Johnson they are pulling back in some areas because of a drop off in domestic leisure travel.

Angie Swint, senior vice president of broadcasting for the Texas Rangers baseball club, joined KRLD's David Johnson in the CEO Spotlight.

Join Brad Logan and David Johnson as they discuss Ole Miss athletics. Coach Yo is red hot in the transfer portal.

Chris Kelly, the president and CEO of HomeServices of America, joined KRLD's David Johnson in the CEO Spotlight.

Ole Miss sports update, David Johnson is back!

David Johnson discusses Psalm 111:10—“The fear of the LORD is the beginning of wisdom; a good understanding have all those who do His commandments. His praise endures forever.”

Wilbur Ross, former U.S. Secretary of Commerce, joined KRLD's David Johnson in the CEO Spotlight.

The Clinch River in Southwest Virginia is one of the oldest rivers in the world. And it's home to 50 different mussel species. But many of them are endangered. Bruce Cahoon and his students may have recently found a clue about what's causing the die offs. And: Virginia's marshes are so thick and tough, hardly anything eats them. Except for purple crabs. They eat the grass and the root, leaving behind nothing but a muddy wasteland. David Johnson says armies of these purple crabs are decimating salt marshes up and down the east coast of the United States. Later in the show: Virginia's bay scallops virtually went extinct in the 1930's. The culprit? A disease that killed off their natural habitat of seagrass. But Chris Patrick and Richard Snyder have recently brought them back from the brink of collapse. Plus: Cholera is no joke. It causes extreme diarrhea in humans and can be deadly within hours. Alison Burke studies what she calls the “cousin of cholera.” It's a bacteria like cholera found in warm waters that lives and spreads in oysters. She's looking to use a special kind of virus called a bacteriophage to decontaminate oysters before they wind up on our plates.

Eric Topchik, the owner and CEO of Galaxy Golf Cars, joined KRLD business analyst David Johnson in the CEO Spotlight.

David Johnson discusses Proverbs 20:12—“The hearing ear and the seeing eye, the LORD has made them both” (Proverbs 20:12).